



FOR IMMEDIATE RELEASE

January 28, 2009 -- Gerold L. Mosher, Ph.D., Joins Verrow Pharmaceuticals as Chief Science Officer

LENEXA, KS -- Verrow Pharmaceuticals, Inc., has added Gerold L. Mosher, Ph.D., to its management team in the role of Chief Science Officer and Vice President of Product Development. In this role Dr. Mosher will be primarily responsible for coordinating product development.

"Dr. Mosher is a great addition to Verrow. He brings extensive experience to our company as we move our products from the research labs into full development," says CEO Dr. Vernon Rowe. "Dr. Mosher is also a leading expert in the pharmaceutical use of cyclodextrins, which are integral to Verrow's kidney-protecting technology."

Prior to joining Verrow, Dr. Mosher was most recently Senior Director of Product Development at CyDex Pharmaceuticals, a Kansas City area company specializing in the use of substituted cyclodextrin technology for solubilization and stabilization of intravenous drug formulations. Dr. Mosher received his Ph.D. degree in pharmaceutical chemistry at the University of Kansas and worked at both Eli Lilly and Merck before moving to CyDex. He is an inventor on over a dozen patents and patent applications in drug delivery.

"Dr. Mosher's addition will greatly facilitate the development of Veropaque, a safer radiocontrast agent," says Geoffrey O. Hartzler, M.D., an interventional cardiologist and consultant to the company. "Veropaque could revolutionize the use of iodinated contrast agents, making them safer wherever they are used."

ABOUT VERROW

Verrow Pharmaceuticals, Inc. (www.verrow.com), a drug development company founded in 2006, is building a portfolio of lead products based on proven drugs by making them less toxic, utilizing a proprietary platform technology.

Two pipeline products have already been discussed with the FDA in preIND meetings: Vertrexate, a novel treatment for secondary progressive multiple sclerosis (SPMS); and Verplatin, a safer formulation of a platinum-containing anti-cancer agent.

Preparations are currently underway for a pre-IND meeting on Veropaque. This product could be used to make contrast-enhanced CT scans and body angiography safer. It could also be used by cardiologists using stents and other devices, where kidney protection is essential.

The modification of existing drugs allows regulatory approval through the abbreviated 505(b)(2) pathway, a cost- and time-saving strategy that has been validated by the FDA's response to Verrow's first two pre-IND submissions.

8550 Marshall Drive, Suite 110, Lenexa, KS 66214 913 647 8000 (phone) 913 647 8001 (fax)